Valsts: Dienvidāfrikas Republika
Valoda: angļu
Klimata pārmaiņas: South African Health Products Regulatory Authority (SAHPRA)
Lennon
BRAZEPAM-3 and BRAZEPAM-6 TABLETS SCHEDULING STATUS: S5 PROPRIETARY NAME (and dosage form): BRAZEPAM-3 and BRAZEPAM-6 TABLETS COMPOSITION: Each tablet contains 3 or 6 mg bromazepam per tablet. PHARMACOLOGICAL CLASSIFICATION: A 2.6 Tranquillizers. PHARMACOLOGICAL ACTION: Bromazepam is a benzodiazepine which has anxiolytic, sedative, muscle relaxant and anticonvulsant properties. In low doses it diminishes anxiety and tension. In higher doses the sedative and muscle-relaxant properties appear. INDICATIONS: Bromazepam is used in the treatment of patients suffering from anxiety disturbances. Bromazepam is only indicated when the disorder is severe, disabling or subjecting the individual to extreme stress. CONTRA-INDICATIONS: Brazepam is contra-indicated in children and in patients with a known hypersensitivity to bromazepam and should not be given to patients with acute closed-angle glaucoma and myasthenia gravis. Bromazepam should not be used for the treatment of chronic psychosis or for phobic or obsessional states. Caution should be observed when giving bromazepam to patients with impaired hepatic or renal function. In elderly and debilitated patients, and patients with impaired obstructive airways disease large doses may produce syncope. Use of bromazepam in the first trimester of pregnancy has been associated with various congenital malformations in the infant and in the last trimester it has been associated with drowsiness, respiratory depression and intoxication in the new born infant. For these reasons bromazepam is contra-indicated in pregnancy. Bromazepam is exerted in breast milk and is contra-indicated by nursing mothers because of the side-effects it can cause in the breastfed infant such as drowsiness, slow heartbeat and breathing problems. WARNINGS: There is potential for ab Izlasiet visu dokumentu